Leming Pharmaceutical (Suzhou)

Leming Pharmaceutical (Suzhou) Co., Ltd. is a high-tech pharmaceutical company founded in 2019, with its predecessor being Shanghai Lindmik Biotechnology Co., Ltd., established in 2001. The company, led by Chairman Mr. Gu Danhui, focuses on the research, development, production, and sales of innovative pharmaceutical preparations, with a specialization in transdermal drug delivery systems. Headquartered in Suzhou Wuzhong Biomedical Industrial Park, Leming also operates an R&D center in Beijing and has business development departments in the United States and Japan to manage the licensing of overseas projects.

The company has developed a technology platform that includes cataplasms (gel patches), tapes (hot-melt adhesive patches), and patches (solvent adhesive patches). Its business model combines in-house R&D with a "license-in" strategy to introduce advanced technologies like nano-based and microsphere drug delivery. Leming is preparing for a shift from being R&D-driven to full commercialization, with a production capacity of 500 million patches per year. Two of its core products, flurbiprofen gel paste and loxoprofen sodium gel paste, are in the late stages of regulatory review.

Leming has secured significant funding to support its growth and industrialization. A recent Series B funding round in June 2024 raised nearly 100 million yuan (approximately $13.8 million), led by CICC Private Equity and with participation from investors like Chengming Capital, Fuhui Venture Capital, and Ruihe Capital. This follows a Series A round in May 2023. The capital is intended to accelerate the development, production, and commercial launch of its core products. The company has established strategic partnerships with major pharmaceutical distributors like Kyushu Tong and Sinopharm Holdings to ensure broad market access upon product approval.

Keywords: transdermal drug delivery, pharmaceutical preparations, gel patches, flurbiprofen, loxoprofen sodium, innovative drug delivery, nano-based drug delivery, microspheres, pharmaceutical R&D, pharmaceutical manufacturing, CICC Private Equity, Fuhui Venture Capital, Ruihe Capital, drug commercialization, high-tech pharmaceutical, Suzhou, clinical needs, differentiated preparations, hot-melt adhesive patch